Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OrthocellASX:OCC +3.92%61 Equity-to-Asset is 0.69 as of Dec. 2025, which is 23% above its 10-year median of 0.56. GuruFocus rates ASX:OCC with a GF Score™ of 61/100 and a GF Value™ of A$1.56 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 1,415 Biotechnology companies, Orthocell ranks better than 51.17% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Orthocell's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$41.16 Mil. Orthocell's Total Assets for the quarter that ended in Dec. 2025 was A$59.80 Mil.
Therefore, Orthocell's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.69.
The historical rank and industry rank for Orthocell's Equity-to-Asset or its related term are showing as below:
ASX:OCC'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.09 Med: 0.56 Max: 0.93
Current: 0.69
During the past 12 years, the highest Equity to Asset Ratio of Orthocell was 0.93. The lowest was 0.09. And the median was 0.56.
ASX:OCC's Equity-to-Asset is ranked better than 51.17% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs ASX:OCC: 0.69
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Orthocell Equity-to-Asset Related Terms
Orthocell Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Orthocell's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:OCC vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Orthocell's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orthocell Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orthocell's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Orthocell's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Orthocell's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orthocell (ASX:OCC) has a Equity-to-Asset of 0.69 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Orthocell and its competitors. This is 23% above median its historical median of 0.56. Over the past decade, Orthocell's Equity-to-Asset has ranged from 0.09 to 0.93. According to the industry distribution chart, Orthocell ranks #691 out of 1415 companies in the Biotechnology industry, placing it in the top 48.8%.
Is Orthocell's Equity-to-Asset too high?
Orthocell's current Equity-to-Asset of 0.69 is 23% above median its 10-year median of 0.56. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.93. The Biotechnology industry median Equity-to-Asset is 0.68. Orthocell's value of 0.69 is 1.5% above this industry median. Based on the distribution chart, Orthocell ranks #691 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Orthocell has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orthocell's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Orthocell ranks #691 out of 1415 companies for Equity-to-Asset. This puts Orthocell in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Orthocell's value of 0.69 is 1.5% above this benchmark. Historically, Orthocell's own Equity-to-Asset has ranged from 0.09 to 0.93 over the past decade. While the company's 10-year median is 0.56 vs. the industry median of 0.68, Orthocell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orthocell's current Equity-to-Asset of 0.69 is 1.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Orthocell and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orthocell's current Equity-to-Asset is 0.69, which is 23% above median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthocell stock overvalued right now?
Based on GuruFocus' analysis, Orthocell (ASX:OCC) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.56, compared to a current price of A$0.80 — trading 49% below its estimated fair value. The current Equity-to-Asset is 0.69, which is 23% above median its 10-year median of 0.56 and 1.5% above the Biotechnology industry median of 0.68. Orthocell's overall GF Score™ is 61/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Orthocell (ASX:OCC), the current Equity-to-Asset is 0.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orthocell (ASX:OCC) Overvalued in 2026?
Based on GuruFocus' analysis, Orthocell stock appears to be undervalued.
The current stock price of A$0.80 is trading 49% below its estimated GF Value™ of A$1.56.
GuruFocus considers Orthocell to be Possible Value Trap.
Key valuation signals for ASX:OCC:
Equity-to-Asset: 0.69 (23% above median its 10-year median of 0.56)
GF Value™: A$1.56 vs. price of A$0.80 (49% below fair value)
Industry Position: 1.5% above the Biotechnology median (#691 of 1415)
No single metric tells the full story. See the ASX:OCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir, which is a collagen wrap used in peripheral nerve repair; and OrthoACI, an implant used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline, such as Tendon Cell Therapy and Collagen Medical Device Platform.
61GF Score
Get the complete analysis for ASX:OCC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OCC has been successfully added to your 
